Comparative Pharmacology
Head-to-head clinical analysis: PERMITIL versus PROMAZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PERMITIL versus PROMAZINE HYDROCHLORIDE.
PERMITIL vs PROMAZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antagonist at dopamine D2 receptors, also blocks alpha-1 adrenergic, histaminergic, and muscarinic receptors.
Promazine hydrochloride is a phenothiazine antipsychotic that blocks postsynaptic dopamine D2 receptors in the mesolimbic system, as well as histamine H1, alpha-1 adrenergic, and muscarinic cholinergic receptors. It also has moderate serotonin and weak serotonin-dopamine antagonist effects.
2.5-10 mg orally every 8-12 hours; maximum 40 mg/day. For severe psychosis: initial 10 mg IM, then 5-10 mg IM every 6-8 hours; maximum 30 mg/day IM.
25-50 mg intramuscularly every 4-6 hours as needed. Maximum 150 mg/day.
None Documented
None Documented
Terminal elimination half-life: 20-30 hours; clinically, steady-state achieved in 5-7 days; prolonged in elderly and hepatic impairment
Terminal elimination half-life: 12-18 hours; in elderly or hepatic impairment may extend to 30 hours
Renal: <1% unchanged; Hepatic: extensively metabolized, metabolites excreted in urine (50-60%) and feces (30-40%)
Primarily renal (approx. 70-80% as metabolites, <1% unchanged); minor biliary/fecal (approx. 15-20%)
Category C
Category C
Antipsychotic
Antipsychotic